 Intercept Pharmaceuticals experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday. The post Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients appeared first on Investors Business Daily. 